Use of Progenitor Biological Bandages in Burn Care (Bru_PBB)

Launched by DR ANTHONY DE BUYS ROESSINGH · Apr 14, 2022

Keywords

ClinConnect Summary

The clinical trial titled "Use of Progenitor Biological Bandages in Burn Care (Bru_PBB)" is studying a new treatment for burn injuries, specifically looking at how effective Progenitor Biological Bandages (PBB) can be in healing burn wounds compared to standard care methods. These bandages contain special cells that can help the skin heal better and faster, especially for patients with second and third-degree burns. The goal is to see if using PBB can reduce the need for painful skin grafts, which involve taking healthy skin from one part of the body and placing it on the burned area.

To be eligible for this trial, participants should be from various age groups: children as young as two years old with burns covering at least 5% of their body, older children and teens with larger burns, and adults over 18 with burns covering 20% or more. Participants will be closely monitored for up to five years after their injury to assess how well the PBB works and to ensure it is safe. It's important to note that this trial is not yet recruiting participants, and certain conditions, like infections or allergies to certain products, may prevent someone from joining the study. Overall, this trial represents a promising step forward in burn care, aiming to improve healing and reduce complications for patients.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • ≤ 2 years old with ≥5% TBSA
• • between 3 and 10 years old with ≥10% TBSA
• • between 11 and 18 years old with ≥15% TBSA
• • ≥ 18 years old with ≥ 20% TBSA
• • ≥ 65 years old with ≥ 10% TBSA
• • Any age with burns on the face, hands, genitalia or major joints
• • Patient with 2nd (superficial to deep) degree burn wounds
• • Patient with 3rd degree burns candidate for a skin autograft
• • Informed Consent as documented by signature and according to consent in case of emergency situation
• • First injury
• • Possibility of Follow-up for 5 years after injury
• Exclusion Criteria:
• • Infected wounds
• • Vitally unstable patients
• • Known allergy or hypersensitivity to product of equine origin
• • Refusal of the study by the participants or relatives